VERICEL CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- VERICEL CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 675.64K shares, a 56.26% decline from fiscal 2024.
- VERICEL CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 1.54M shares, a 309.07% increase from fiscal 2023.
- VERICEL CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 377.60K shares, a 60.88% increase from fiscal 2022.
- VERICEL CORPORATION share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 234.71K shares, a 75.76% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 675.64K shares 10-K · filed 2026-02-26 | |
| 2024-12-31 | 1.54M shares 10-K · filed 2025-02-27 | |
| 2023-12-31 | 377.60K shares 10-K · filed 2024-02-29 | |
| 2022-12-31 | 234.71K shares 10-K · filed 2023-02-23 | |
| 2021-12-31 | 968.26K shares 10-K · filed 2022-02-24 | |
| 2020-12-31 | 790.53K shares 10-K · filed 2021-02-24 | |
| 2019-12-31 | 1.20M shares 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |